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Abstract
Background: The Response Evaluation Criteria in Solid Tumors (RECIST) guideline and Common Terminology
Criteria for Adverse Events (CTCAE) criteria are used to assess chemotherapy efficiency and toxicity in patients with
advanced lung cancer. However, no real-time, synchronous indicators that can evaluate chemotherapy outcomes
are available. We wanted to evaluate tumor response and toxicity in advanced lung cancer chemotherapy by using
a novel synchronous strategy.
Results: We enrolled 316 patients with advanced lung cancer who were treated with cisplatin-based therapy and
followed up them for 3 years. Plasma was obtained before and after every chemotherapy cycle. We quantitative
assayed total plasma DNA and methylation of the APC/RASSF1A genes. Four parameters were assessed: methylation
level before chemotherapy (meth0 h), methylation level 24 h after chemotherapy (meth24 h), total plasma DNA
concentration before chemotherapy (DNA0 h), and total plasma DNA concentration 24 h after chemotherapy
(DNA24 h). When meth24 h > meth0 h of at least one gene was used to predict tumor response, the correct
prediction rate was 82.4 %. Additionally, patients for whom DNA24 h/DNA0 h ≤ 2 had mild toxicities. Therefore,
meth24 h > meth0 h and DNA24 h/DNA0 h ≤ 2 were defined as criteria for better tumor response and fewer adverse
events with a high correct prediction rate (84.7 %).
Conclusions: Quantitative analysis of total plasma DNA and plasma APC/RASSF1A methylation provide a real-time
synchronous rapid monitoring indicator for therapeutic outcomes of advanced lung cancer, which could be a
reference or supplementary guidelines in evaluating chemotherapy effects.
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Background
Patients with advanced lung cancer (ALC) are usually di-
agnosed after metastasis has occurred and therefore re-
quire chemotherapy. However, the high mortality rate and
low 5-year survival rate are partly because of resistance to
currently available chemotherapy regimens and ineffective
monitoring methods for chemotherapy efficacy [1–9].
Several years ago, scholars suggested the notion of real-
time apoptosis monitoring, the key point of which was the
necessity to find a real-time monitor to provide the infor-
mation about whether the chemotherapy was working
[10]. The current Response Evaluation Criteria in Solid
Tumors (RECIST) guideline, which is based on tumor size
measured by chest X-ray or CT scan, and widely used
tumor markers assay (such as carcinoembryonic antigen
(CEA) and neuronal specific enolase (NSE)) are not sensi-
tive enough to monitor chemotherapy effects in an indi-
vidual patient because these markers require more than a
month after chemotherapy to provide the information of
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interest. Consequently, no synchronous indicator that can
rapidly evaluate chemotherapy outcomes is available.
Reportedly, total circulating DNA, derived from nec-
rotic or apoptotic cells, can come from both normal cells
and tumor cells. In a normal state, total circulating DNA
is at a low level—mainly from a few apoptotic normal
cells (usually lymphocytes and other nucleated cells)
[11]. However, when both normal and tumor cells are
killed by chemotherapy drugs, total circulating DNA will
obviously increase; DNA from the normal cells will re-
flect the side effects of the drugs. Because aberrant genes
hypermethylation usually occurs in neoplastic and ab-
normally differentiated cells [12–15], elevated gene
methylation levels will be present if many cancer cells
are killed by chemotherapy drugs (Additional file 1:
Figure S1). Therefore, circulating tumor DNA with
abnormal methylation patterns can be detected with a
notable degree of specificity, even in the presence of
excess DNA from normal cells. This was the start
point for the present study to use total circulating
DNA and methylation assays as indicators of the effi-
cacy of chemotherapy in ALC patients.
Though many studies have been interested in the rela-
tionship between prognosis and methylation levels in
tumor suppressor genes (TSGs), research that focuses
on indicators that can simultaneously monitor not only
tumor response but also toxicity after chemotherapy is
rare. We designed this prospective research to present a
detailed study on the quantitative dynamic alteration of
APC/RASSF1A methylation levels before and after
chemotherapy cycles and to combine assays of APC/
RASSF1A methylation and total plasma DNA in the
hope of providing a new strategy to monitor efficiency
and toxicity of chemotherapy in ALC.
Results
Methylation levels increased 24 h after cisplatin
administration in A549 cells and in tumor-bearing nude
mice
To determine whether APC or RASSF1A gene pro-
moters were methylated in A549 cells, we first assayed
the methylation status of this cell line compared with
H460 cells, which acted as a positive control. Ct values
of APC and RASSF1A were 28.5 and 29.7 for H460 and
28.2 and 29.6 for A549, respectively, demonstrating posi-
tive methylation of APC and RASSF1A in A549 cells
(Additional file 2: Figure S2).
A549 cell supernatant was tested for its methylation sta-
tus at 6, 12, 24, 48, and 72 h after treatment with different
concentrations of cisplatin (Fig. 1). First, an 3-(4,5-
dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium brom-
ide (MTT) assay (Fig. 1a) indicated that A549 cells were
sensitive to 5 mg/ml cisplatin (inhibition rate >50 %). Sec-
ond, under this optimal cisplatin dose (5 mg/ml), methyla-
tion of APC or RASSF1A peaked at 24 h (Fig. 1b, c).
For a better understanding of changes in methylation
status of the two genes after cisplatin treatment, we used
a tumor-bearing nude mouse model (Fig. 1d, e). The
methylation rates of APC or RASSF1A in the plasma of
tumor-bearing nude mice were highest at 24 h after
injection. Biopsies showed that most tumor cells in the
tissues of group 1 (treated with cisplatin) were dead,
whereas tumor cells in group 2 (treated with normal sa-
line) were still proliferating (Fig. 1f, g).
Fig. 1 Methylation levels increased 24 h after cisplatin administration in A549 cells or in tumor-bearing nude mice. a MTT assay showed that
A549 cells were sensitive to 5 mg/ml cisplatin. Error bars mean ± SD (n = 3). b The peak methylation level of APC in A549 cells was at 24 h after
cisplatin treatment. c The peak methylation level of RASSF1A in A549 cells was at 24 h after cisplatin treatment. Methylation rates of d APC and
e RASSF1A were highest at 24 h after cisplatin injection in tumor-bearing nude mice injected with NS and cisplatin (group 1). f Pathological biopsy
of tumor tissues for tumor-bearing nude mice injected with NS (group 2). Most tumor cells in the tissues were alive at 72 h after injection (×200).
g Biopsy of tumor tissues for mice of group 1. Tumor cells in the tissues had nearly all died at 72 h after injection (×200)
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Fig. 2 (See legend on next page.)
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Elevated methylation level after cisplatin-based
chemotherapy was correlated with good tumor response
in ALC patients of training study
Before chemotherapy, methylation frequencies of APC
and/or RASSF1A were 48.9 % (46/94) in adenocarcin-
oma, 50.0 % (28/56) in squamous carcinoma, and 39.4 %
(26/66) in other histological types. After two chemother-
apy cycles, 123 patients had elevated APC and/or
RASSF1A methylation (elevated gene methylation means
the methylation level at 24 h [meth24 h] after the chemo-
therapy cycle was higher than that before chemotherapy
[meth0 h], that is, meth24 h > meth0 h). The efficient re-
sponse rate (ERR) was 75.6 % (93/123). Among the 123
patients, there were 83.5 % (101/121), 64.7 % (77/119),
and 85.6 % (95/111) cases whose CEA, NSE, and CY21-
1 levels decreased. In the remaining 93 patients, who
were without elevated APC/RASSF1A methylation, the
ERR was 8.6 % (8/93), significantly lower than those with
meth24 h > meth0 h of at least one gene (P < 0.01). CEA,
NSE, and CY21-1 levels decreased in 12.9 % (12/93),
21.2 % (18/85), and 15.4 % (10/65) of these 93 patients
(Fig. 2a). When we used meth24 h > meth0 h of at least
one gene to predict tumor response, the correct predic-
tion rate was 82.4 % [(93 + 37 + 48)/216].
We performed overall survival (OS) rate analyses ac-
cording to increases in gene methylation levels after
chemotherapy (Fig. 2b–d). The median survival was differ-
ent between patients with methylation level elevation and
those without elevation of APC or RASSF1A methylation.
The above results seemed to suggest that the meth24 h >
meth0 h of at least one gene is correlated with good re-
sponse to cisplatin-based chemotherapy in ALC patients.
Large amounts of clinical data taken over a 3-year follow-
up also confirmed this opinion (Fig. 2e–h).
Elevated total plasma DNA after cisplatin-based
chemotherapy was correlated with the adverse events
grade in ALC patients of training study
Toxicities were evaluated after the first chemotherapy.
From 216 paired plasma samples (before and 24 h after
medication), we got the changes of total plasma DNA:
total plasma DNA concentration at 24 h after medica-
tion (DNA24 h) was less than or equal to twofolds of that
before medication (DNA0 h) in 132 cases (DNA24 h/
DNA0 h ≤ 2) and DNA24 h was more than twofolds of
DNA0 h in 84 cases (DNA24 h/DNA0 h > 2). Toxicities of
platinum-based regimens, especially hepatotoxicity,
nephrotoxicity, and gastrointestinal symptoms, mainly
occurred in the 84 DNA24 h/DNA0 h > 2 cases (Fig. 3a).
The incidence of adverse events in the DNA24 h/
DNA0 h > 2 case group was higher than that in the
DNA24 h/DNA0 h ≤ 2 case group (39.53 vs. 28.69 %, P <
0.05). Especially, the incidence of adverse events above
grade 1 in the DNA24 h/DNA0 h > 2 case group was signifi-
cantly elevated compared with that in the DNA24 h/
DNA0 h ≤ 2 case group (13.18 vs. 6.77 %, P < 0.05, Fig. 3b).
Combined APC/RASSF1A methylation and total plasma
DNA assay was consistent with clinical judgment in ALC
patients of training study
After the second chemotherapy cycle, we found 123 pa-
tients who were meth24 h > meth0 h for APC and/or
RASSF1A, 93 who were meth24 h ≤meth0 h for both
genes, 67 were DNA24 h/DNA0 h > 2 patients, and 149
were DNA24 h/DNA0 h ≤ 2 patients. Monitoring per-
formance of combined APC/RASSF1A methylation and
total plasma DNA assay, and the clinical judgment of
tumor response and toxicity degree, is shown in Fig. 4a.
Patients in quadrant I to quadrant IV were 47, 26, 67,
and 76, respectively. In quadrant I, clinical judgment
(tumor response and toxicity) was consistent with com-
bined methylation and total plasma DNA assay in 38
cases. The coincidence rate was 80.9 % (38/47). Likewise,
the coincidence rates were 84.6 % (22/26), 85.1 % (57/67),
and 86.8 % (66/76) in quadrants II to IV, respectively.
Therefore, the use of combined APC/RASSF1A
methylation and total plasma DNA assay to predict
chemotherapy outcome gave a correct prediction rate
of 84.7 % [(22 + 57 + 38 + 66)/216].
Further confirmation of the combined indicator in
validation study
After the second chemotherapy cycle, 54 patients were
judged to have complete response (CR)/partial response
(PR) and mild adverse events; of these, 85.2 % (46/54)
had “meth24 h > meth0 h” of at least one gene and
“DNA24 h/DNA0 h ≤ 2”. In contrast, 28 patients had
stable disease (SD)/progressive disease (PD) and
(See figure on previous page.)
Fig. 2 Elevated methylation level after cisplatin-based chemotherapy was correlated with good tumor response in ALC patients of training study.
a Tumor response evaluation and tumor markers levels. In patients with elevated APC and/or RASSF1A methylation level, the efficient response
rate (ERR) was higher; most cases had decreased tumor markers levels. b Kaplan–Meier curve for OS of patients with and without elevated APC
methylation levels (median OS, 18 vs. 9 months, P < 0.05). c Kaplan–Meier curve for OS rates of patients with and without upregulated RASSF1A
methylation levels (median OS, 20 vs. 8 months, P < 0.05). d Kaplan–Meier curves for OS rates of patients with elevated methylation levels of at
least one gene and those without increased APC or RASSF1A methylation (median OS, 25 vs. 6 months, P < 0.01). e–h Methylation status and CT
scan images of four representative patients. e, f Two patients died within 4 and 5 months of diagnosis, respectively. g, h Two patients remained
alive during this study
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Fig. 3 Elevated total plasma DNA after cisplatin-based chemotherapy was correlated with the adverse events grade in ALC patients of training
study. a Toxicities of platinum-based regimens mainly occurred in 84 cases with DNA24 h/DNA0 h > 2, especially hepatotoxicity, nephrotoxicity,
and gastrointestinal symptoms. b The incidence of adverse events above grade 1 in the DNA24 h/DNA0 h > 2 case group was significantly elevated
compared with that in the DNA24 h/DNA0 h ≤ 2 case group (13.18 vs. 6.77 %, P < 0.05)
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Fig. 4 (See legend on next page.)
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moderate/severe adverse events, of whom 82.1 % (23/28)
showed no APC/RASSF1A methylation elevation or had
very high DNA24 h. Ten patients have CR/PR and moder-
ate/severe adverse events, 80 % (8/10) had “meth24 h >
meth0 h” of at least one gene and DNA24 h/DNA0 h > 2.
Eight patients have SD/PD and mild adverse events, 75 %
(6/8) showed no APC/RASSF1A methylation elevation and
“DNA24 h/DNA0 h ≤ 2”. Dynamic observation of cycles dur-
ing follow-up was also analyzed. Figure 4b–d shows
changes in total plasma DNA, APC/RASSF1A methylation,
and clinical adverse events from three randomly chosen pa-
tients. This information also confirmed that patients with
“meth24 h >meth0 h” of at least one gene and “DNA24 h/
DNA0 h ≤ 2” had better tumor response and fewer adverse
events.
Discussion
Chemotherapy is usually the treatment of choice to
improve the quality of life and prolong survival time
of patients with advanced cancers. The response of
malignant tumors to chemotherapy varies, and some
clinical trials have shown that patients with advanced
cancer who received personalized chemotherapeutic
regimens or drug doses fared better than those
treated with standard chemotherapy [16, 17], which
has led to increased focus on personalized medicine
[18]. However, existing detection means are not sensi-
tive and timely enough to provide adequate informa-
tion about chemosensitivity.
Cell death reportedly results in the release of DNA
into the circulation, which peaks at 24 h and gradually
declines [19, 20]. Results of cell lines and nude mouse
studies showed us the dynamic changes of APC and
RASSF1A methylation on both lung adenocarcinoma cell
line (A549) and large cell lung cancer cell line (H460)
and indicated that peak methylation increase is also at
24 h after cisplatin administration.
Many studies have shown the high methylation fre-
quency of APC and RASSF1A in the plasma of lung can-
cer patients [21–28]. Therefore, we chose the two genes
and originated the duplex quantitative methylation spe-
cific PCR (qMSP) method to assess their promoter
methylation. The feature of this new method is simul-
taneous detection of both genes’ methylation. Several
studies have found differences in the methylation fre-
quencies of APC or RASSF1A among the particular
histological types of lung cancer [29–33]. The reason of
these conflicting findings may be the difference in detec-
tion sites of the two genes’ promoters. Moreover, we offer
both APC and/or RASSF1A to diminish the influence of
histological type that might be caused by using a single
gene. Additionally, we compared methylation frequencies
of APC/RASSF1A with other five studies [32, 34–37] (Add-
itional file 3: Table S1). The results showed no significant
sample selection bias in the present study. Therefore, our
APC/RASSF1A methylation application for lung cancer
prognosis is reliable.
Therefore, we detected the quantitative methylation
levels of APC and RASSF1A before and 24 h after the
chemotherapy cycles to evaluate tumor response in lung
cancer patients. According to the results, we confirmed
our hypothesis that meth24 h > meth0 h is a predictor of
sensitivity to cisplatin-based chemotherapy in lung can-
cer patients. The explanation of this hypothesis is as fol-
lows: if the tumor cells are sensitive to chemotherapy
drugs, they will be heavily destroyed and lead to a tem-
porary mass release of DNA. Therefore, at 24 h after
medication, circulating DNA levels will be higher than
that before medication. As indicated in quadrant IV of
Fig. 4a, circulating DNA of patients with good drug re-
sponse was mainly from cancer cells, while circulating
DNA of patients with severe toxicity (quadrant II, Fig. 4a)
was mainly from healthy cells.
Moreover, Kaplan–Meier analysis and the dynamic
methylation monitoring of patients also indicate that
Fig. 5 The strategy of using combined APC/RASSF1A methylation and total plasma DNA to assess chemotherapy response and toxicity and to
adjust regimens
(See figure on previous page.)
Fig. 4 Combined APC/RASSF1A methylation and total plasma DNA assay was consistent with clinical judgment in ALC patients. a Patients with
different methylation status and plasma DNA level had different tumor response and degrees of adverse events. The coincidence rates were
80.9, 84.6, 85.1, and 86.8 % in quadrants I to IV, respectively. b–d Methylation status, plasma DNA level, and some clinical information of three
patients in the validation model. b A male patient died within 5 months of diagnosis. c A female patient had been alive for 36 months by the
end of follow-up. d A patient had been alive nearly 24 months by the end of follow-up
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patients with increased APC or RASSF1A methylation
levels after cisplatin-based chemotherapy have better
outcomes. Additionally, although a patient’s tumor le-
sion may undergo alterations which are characteristics
of remission after effective therapy, the symptoms do
not typically present in time. So before we can observe
obvious symptoms and signs, most patients (82.4 %) can
use APC and RASSF1A methylation assay after every
chemotherapy cycle to predict tumor response. There-
fore, methylation detection of plasma at 24 h after medi-
cation is a promising earlier and timing indicator than
some tumor markers or CT scanning.
At the last part of the training study, we assayed total
plasma DNA to monitor toxicity of chemotherapy in ALC
patients. This content shows that toxicity is more com-
mon in patients with excessively elevated plasma DNA
(DNA24 h/DNA0 h > 2). Therefore, when combined with
APC/RASSF1A methylation, there were three models:
(1) APC and/or RASSF1A methylation levels increase
with DNA24 h/DNA0 h ≤ 2. This model indicates
that patients will benefit from this chemotherapy
regimen without severe toxicity. Therefore, to get
a better chemotherapy effect, patients can receive
higher dosage of chemotherapy drugs while
monitoring both total plasma DNA and APC/
RASSF1A methylation levels.
(2) APC and/or RASSF1A methylation levels increase
with DNA24 h/DNA0 h > 2. In this model, good
tumor response and obvious toxicity co-exist. Thus,
dosage may need adjustment (usually downward) to
avoid severe side effects.
(3) APC and RASSF1A methylation levels never increase
no matter how total plasma DNA changes. In
this model, tumor cells are not sensitive to the
chemotherapy regimen. Hence, the regimen is
not an optimal choice and should be changed
immediately.
Based on the above results of this study, we offer a
new strategy to assess the efficiency and toxicity of
chemotherapy for ALC (Fig. 5), according to which clini-
cians can adjust chemotherapy regimens in time.
Conclusions
We were able to demonstrate that quantitative assay
of total plasma DNA and APC/RASSF1A methylation
levels can rapidly and simultaneously predict tumor
response and toxicity to cisplatin-based chemotherapy
in ALC patients. Especially, the quantitative methyla-
tion assay of TSG can show chemosensitivity 24 h
after chemotherapy cycles, which is much faster than
the imaging-based examinations used in the RECIST
guideline. Furthermore, plasma DNA and TSG methy-
lation assays are simple and non-invasive tools, con-
venient for follow-up and repeated sample collection.
The new strategy shown in Fig. 5 may therefore pro-
vide a reference or supplement to guidelines in evalu-
ating chemotherapy effects.
Methods
Cell culture, MTT assay, and supernatant collection
Human lung adenocarcinoma A549 cells (Shanghai
Institutes for Biological Sciences, China) were seeded
in triplicate at a density of 1.5 × 104 cells/100 μl in
96-well plates and grown at 37 °C in a humidified at-
mosphere containing 5 % CO2. After 24 h, 100 μl/
well cisplatin was added to the cells at three final
concentrations (5, 0.5, and 0.05 mg/ml). Cells without
cisplatin treatment served as controls. At 0, 6, 12, 24,
48, and 72 h after administration, the culture super-
natant was collected. Then, 20 μl MTT (5 mg/ml)
was added to each well, and the plate was incubated
at 37 °C for another 4 h, after which 10 % HCL-SDS
(100 μl) was added to each well. Cell proliferation
was determined using a 96-well plate reader to record
the absorbance at 570 nm. The inhibition percentage
of A549 cell proliferation was calculated using the
following formula: inhibition rate = ([absorbance of
control well] − [absorbance of administration well])/
[absorbance of control well] × 100 %. Data are expressed
as mean ± SD of triplicate wells and are representative of
at least two independent experiments.
Nude mouse model of lung adenocarcinoma and blood
or tumor tissues collection
Twenty-four nude mice were purchased from Shanghai
SLAC Laboratory Animal Company. Eight mice were
designated as control group, and two of which died. The
other 16 nude mice were used to establish a lung adeno-
carcinoma model by subcutaneous injection of 2 × 106
A549 cells in the hind legs. When tumor diameters were
more than 5 mm after 25 days, the 16 tumor-bearing
nude mice were randomly divided into two groups:
group 1 consisted of eight tumor-bearing nude mice that
were intratumorally injected with 0.2 ml normal saline
(NS) containing 8 μg cisplatin per gram of mouse body
weight for three consecutive days. Group 2 consisted of
eight tumor-bearing nude mice that were intratumorally
injected with 0.2 ml NS for three consecutive days.
Blood and tumor tissues of the four groups and con-
trols were collected at 24, 48, and 72 h after administra-
tion. To obtain plasma, the blood specimens were
centrifuged in two steps at 4 °C (3000 rpm for 10 min
and 16,000 rpm for 10 min) [19]. The tumor tissues
were prepared by H&E staining.
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Advanced lung cancer patients
Patients with stages IIIb and IV ALC were recruited
from the Department of Oncology of the First Affiliated
Hospital of Nanjing Medical University (China) from
October 2007 to June 2009. All patients were followed
until November 2010. Inclusion criteria were (1) histo-
logically or cytology confirmed lung cancer, (2) newly di-
agnosed disease according to the staging system of the
2002 American Joint Committee on Cancer (AJCC), (3)
an age of 18–80 years, (4) unresectable or metastatic dis-
ease, (5) measurable disease, (6) Eastern Cooperative
Oncology Group (ECOG) performance status 0–2, (7)
life expectancy > 3 months, (8) no contraindication for
chemotherapy, and (9) cisplatin-based regimens for two
initial cycles. The exclusion criteria were as follows: (1) a
history of previous malignant neoplasms or other con-
comitant malignant diseases; (2) a history of surgery,
chemotherapy, and radiotherapy; and (3) refusal to have
blood drawn for times needed for this study. All patients
gave informed consent prior to specimen collection ac-
cording to the study, which was reviewed and approved
by the Committee on the Ethics of Treatment of Human
Subjects of The First Affiliated Hospital of Nanjing Medical
University. Two hundred and sixteen patients were in-
cluded in the training study, and flow chart of which is pre-
sented in Fig. 6. Another 100 patients were enrolled in the
validation study. The patients’ characteristics are listed in
Additional file 4: Table S2.
The blood samples in EDTA-containing tubes, which
were used to perform total plasma DNA and methyla-
tion assays, were collected from these patients before
and 24 h after every chemotherapy cycle and were cen-
trifuged in two steps at 4 °C (3000 rpm for 10 min and
16,000 rpm for 10 min) to obtain plasma.
Evaluation of chemotherapy efficiency and toxicity
All the patients were followed for at least four chemother-
apy cycles. Chemotherapy regimens were IP (irinotecan/
cisplatin), DC (docetaxel/cisplatin), and GP (gemcitabine/
cisplatin). Chemotherapy efficacy was evaluated by tumor
response according to the Response Evaluation Criteria in
Solid Tumors (RECIST1.1) [38] 50–60 days after the first
cycle. The main evaluation contents were efficient re-
sponse rate (ERR), tumor markers (detected 2 months
after the first cycle), and overall survival (OS). Efficient
response included complete response (CR) and partial
response (PR). Non-efficient response included stable dis-
ease (SD) and progressive disease (PD). Tumor markers
were CEA, NSE, and CY21-1, which are the most com-
monly used markers in lung cancer. Fifteen main toxicities
were assessed and graded according to the Common
Terminology Criteria for Adverse Events (CTCAE,
Version 4.0) after a single chemotherapy cycle.
DNA extraction from culture supernatant or plasma
DNA was extracted from 200 μl cell culture supernatant or
mouse and patient plasma using the BilaTest DNA Kit
(Bilatec, Viernheim, Germany), according to the manufac-
turer’s recommendations. Briefly, 200 μl of specimen was
mixed thoroughly with lysis solution, poly(A)RNA/protease
solution, and beads/binding buffer, and tubes were placed
on a magnet. After discarding the supernatant, the DNA
Fig. 6 Flow chart of the training study (n = 216)
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was washed twice with washing solution and then eluted
with 40 μl of elution buffer.
Total plasma DNA assay
Duplex real-time PCR was performed to detect total
plasma DNA concentrations, which is described in our
previous study [39].
Duplex qMSP assay of APC and RASSF1A promoter
methylation levels
The NCI-H460 cell line was introduced into this study as
positive control for methylation of APC and RASSF1A, as
previously described [39]. External standard curves were
prepared by serial diluted calibrators and contained
1.5 × 105, 1.5 × 104, 1.5 × 103, and 1.5 × 102 copies/ml
of H460 cell DNA using the plasma of a healthy per-
son as solution matrix. The extracted DNA samples
(50 μl), including that of the cell culture supernatant,
nude mice, patients, and H460 cells, were modified
by sodium bisulfate using a CpGenome DNA Modifica-
tion Kit (Chemicon, USA) based on the principles and
procedure previously described by Herman [40]. To fully
utilize the trace quantity of modified DNA, we developed
a duplex qMSP to measure APC and RASSF1A simultan-
eously in the same tube. Each amplification mix (50 μl)
contained sample DNA (5 μl) with components supplied
in the Takara Ex Taq R-PCR Version 2.1 kit (Takara,
Dalian, China). Each reaction contained 10 μl of 5× real-
time PCR buffer, 400 μM each deoxynucleotide triphos-
phate, 2 mM MgCl2, 200 nM each primer, 170 nM each
probe, and 2U Takara Ex Taq HS. All the primers and
probes used in this protocol were designed by Primer
Express Software Version 3.0 and are listed in Additional
file 5: Table S3. Amplification and real-time measurement
were performed in an Applied Biosystems 7500 Sequence
Detector (Applied Biosystems, CA, USA) under the fol-
lowing conditions: 1 min at 95 °C followed by 55 cycles of
5 s at 95 °C and 34 s at 60 °C. Data obtained during 55 -
cycles of amplification were analyzed. All samples were
tested in triplicate. Blood samples pre- and post-
chemotherapy from one patient were analyzed simultan-
eously. Data are expressed as median and interquartile.
Statistical analysis
All statistical analyses were carried out using Stata9.1 and
SPSS13.0 software. Two-way ANOVA tests were used to
compare methylation levels between treatment and con-
trol groups of A549 cells when three time points were
assessed. The methylation rates between tumor-bearing
nude mice groups were analyzed using the Fisher’s exact
test. Quantitative methylated genes before and after the
first chemotherapy cycle was assessed by the Wilcoxon
matched-pairs signed-rank test. Differences between
groups were analyzed using the Kruskal–Wallis signed-
rank test. Survival curves were calculated using the
Kaplan–Meier method, and comparisons were performed
by the log-rank test. P < 0.05 was considered significant.
Additional files
Additional file 1: Figure S1. Circulating DNA diagram. Total circulating
DNA comes from normal cells and tumor cells, whereas aberrant genes
hypermethylation usually occur in tumor cells. (TIFF 2509 kb)
Additional file 2: Figure S2. Methylation amplification curves for APC
or RASSF1A in A549 cells. (A) Methylation amplification curves for APC
gene promoter. (B) Methylation amplification curves for RASSF1A gene
promoter. The Ct values for APC and RASSF1A gene amplification in A549
cells were close to those of the H460 positive control cells. (TIFF 1393 kb)
Additional file 3: Table S1. Methylation frequency of APC and/or
RASSF1A in present study and other 5 articles. (DOCX 80 kb)
Additional file 4: Table S2. Clinical characteristics of 316 advanced
lung cancer patients. (DOCX 18 kb)
Additional file 5:Table S3. Primers and probes used in duplex qMSP.
(DOCX 13.7 kb)
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meth24 h: methylation level at 24 h after chemotherapy treatment;
NS: normal saline; NSE: neuronal specific enolase; OS: overall survival;
PD: progressive disease; PR: partial response; RECIST: Response Evaluation
Criteria in Solid Tumors; SD: stable disease; TSG: tumor suppressor genes.
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